Kopran Share Price
Sector: Biotechnology & Drugs
185.55 +0.55 (0.30%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
183.95
Today’s High
188.00
52 Week Low
157.00
52 Week High
369.20
185.48 +0.68 (0.37%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
184.27
Today’s High
188.00
52 Week Low
155.00
52 Week High
369.70
Key Metrics
- Market Cap (In Cr) 898.85
- Beta 0.93
- Div. Yield (%) 1.62
- P/B 1.73
- TTM P/E 17.01
- Sector P/E 22.43
- D/E 0
- Open Price 185.75
- Prev Close 185
Kopran Analysis
Price Analysis
-
1 Week-0.75%
-
3 Months5.86%
-
6 Month-14.15%
-
YTD-12.42%
-
1 Year-26.64%
Risk Meter
- 47% Low risk
- 47% Moderate risk
- 47% Balanced Risk
- 47% High risk
- 47% Extreme risk
Kopran News
Madhusudan Kela's wife raises stake in THIS small-cap stock in Q4. Do you own?
2 min read . 10 Apr 2025Buy or sell: Vaishali Parekh recommends three stocks to buy today — January 7
2 min read . 07 Jan 2025Stocks in focus: Rajesh Palviya of Axis Securities recommends three stocks today
3 min read . 06 Sep 2024Kopran Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 629.6
- Selling/ General/ Admin Expenses Total
- 60.54
- Depreciation/ Amortization
- 15.59
- Other Operating Expenses Total
- 91.55
- Total Operating Expense
- 572.3
- Operating Income
- 57.31
- Net Income Before Taxes
- 51.95
- Net Income
- 38.55
- Diluted Normalized EPS
- 7.99
- Period
- 2025
- Total Assets
- 844.01
- Total Liabilities
- 325.66
- Total Equity
- 518.35
- Tangible Book Valueper Share Common Eq
- 102.05
- Period
- 2025
- Cashfrom Operating Activities
- 41.94
- Cashfrom Investing Activities
- -56.43
- Cashfrom Financing Activities
- 25.87
- Net Changein Cash
- 11.38
- Period
- 2024
- Total Revenue
- 614.59
- Selling/ General/ Admin Expenses Total
- 97.35
- Depreciation/ Amortization
- 12.89
- Other Operating Expenses Total
- 3.35
- Total Operating Expense
- 546.61
- Operating Income
- 67.99
- Net Income Before Taxes
- 67.54
- Net Income
- 50.96
- Diluted Normalized EPS
- 10.57
- Period
- 2024
- Total Assets
- 743.25
- Total Liabilities
- 252
- Total Equity
- 491.25
- Tangible Book Valueper Share Common Eq
- 97.41
- Period
- 2024
- Cashfrom Operating Activities
- 43.26
- Cashfrom Investing Activities
- -43.55
- Cashfrom Financing Activities
- 0.99
- Net Changein Cash
- 0.69
- Period
- 2023
- Total Revenue
- 550.99
- Selling/ General/ Admin Expenses Total
- 100.49
- Depreciation/ Amortization
- 12.71
- Other Operating Expenses Total
- 4.36
- Total Operating Expense
- 505.7
- Operating Income
- 45.28
- Net Income Before Taxes
- 36.07
- Net Income
- 27.23
- Diluted Normalized EPS
- 5.65
- Period
- 2023
- Total Assets
- 649.7
- Total Liabilities
- 210.45
- Total Equity
- 439.25
- Tangible Book Valueper Share Common Eq
- 87.77
- Period
- 2023
- Cashfrom Operating Activities
- 34.02
- Cashfrom Investing Activities
- -12.65
- Cashfrom Financing Activities
- -19.84
- Net Changein Cash
- 1.53
- Period
- 2022
- Total Revenue
- 477.52
- Selling/ General/ Admin Expenses Total
- 91.09
- Depreciation/ Amortization
- 11.1
- Other Operating Expenses Total
- 2.58
- Total Operating Expense
- 400.6
- Operating Income
- 76.92
- Net Income Before Taxes
- 81.78
- Net Income
- 61.03
- Diluted Normalized EPS
- 13.77
- Period
- 2022
- Total Assets
- 610.89
- Total Liabilities
- 184.72
- Total Equity
- 426.17
- Tangible Book Valueper Share Common Eq
- 86.18
- Period
- 2022
- Cashfrom Operating Activities
- -33.48
- Cashfrom Investing Activities
- -84.42
- Cashfrom Financing Activities
- 122.82
- Net Changein Cash
- 4.93
- Period
- 2021
- Total Revenue
- 491.81
- Selling/ General/ Admin Expenses Total
- 82.56
- Depreciation/ Amortization
- 10.19
- Other Operating Expenses Total
- 2.22
- Total Operating Expense
- 419.41
- Operating Income
- 72.41
- Net Income Before Taxes
- 83.34
- Net Income
- 61.61
- Diluted Normalized EPS
- 14.26
- Period
- 2021
- Total Assets
- 439.38
- Total Liabilities
- 194.35
- Total Equity
- 245.03
- Tangible Book Valueper Share Common Eq
- 54.64
- Period
- 2021
- Cashfrom Operating Activities
- 59.95
- Cashfrom Investing Activities
- -24.41
- Cashfrom Financing Activities
- -34.57
- Net Changein Cash
- 0.97
- Period
- 2020
- Total Revenue
- 359.5
- Selling/ General/ Admin Expenses Total
- 77.43
- Depreciation/ Amortization
- 9.58
- Other Operating Expenses Total
- 2.94
- Total Operating Expense
- 322.01
- Operating Income
- 37.49
- Net Income Before Taxes
- 28.28
- Net Income
- 21.02
- Diluted Normalized EPS
- 4.97
- Period
- 2020
- Total Assets
- 371.45
- Total Liabilities
- 181.77
- Total Equity
- 189.68
- Tangible Book Valueper Share Common Eq
- 41.88
- Period
- 2020
- Cashfrom Operating Activities
- 31
- Cashfrom Investing Activities
- -12.52
- Cashfrom Financing Activities
- -18.06
- Net Changein Cash
- 0.42
- Period
- 2019
- Total Revenue
- 357.9
- Selling/ General/ Admin Expenses Total
- 78.5
- Depreciation/ Amortization
- 8.74
- Other Operating Expenses Total
- 3.98
- Total Operating Expense
- 320.23
- Operating Income
- 37.67
- Net Income Before Taxes
- 31.66
- Net Income
- 24.02
- Diluted Normalized EPS
- 5.56
- Period
- 2019
- Total Assets
- 352.31
- Total Liabilities
- 183.84
- Total Equity
- 168.48
- Tangible Book Valueper Share Common Eq
- 37.24
- Period
- 2019
- Cashfrom Operating Activities
- 25.41
- Cashfrom Investing Activities
- -24.86
- Cashfrom Financing Activities
- -0.58
- Net Changein Cash
- -0.03
- Period
- 2025-03-31
- Total Revenue
- 172.36
- Selling/ General/ Admin Expenses Total
- 17.26
- Depreciation/ Amortization
- 3.87
- Other Operating Expenses Total
- 22.65
- Total Operating Expense
- 159.15
- Operating Income
- 13.22
- Net Income Before Taxes
- 13.71
- Net Income
- 9.68
- Diluted Normalized EPS
- 2.01
- Period
- 2025-03-31
- Total Assets
- 844.01
- Total Liabilities
- 325.66
- Total Equity
- 518.35
- Tangible Book Valueper Share Common Eq
- 102.05
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 41.94
- Cashfrom Investing Activities
- -56.43
- Cashfrom Financing Activities
- 25.87
- Net Changein Cash
- 11.38
- Period
- 2024-12-31
- Total Revenue
- 166.24
- Selling/ General/ Admin Expenses Total
- 15.4
- Depreciation/ Amortization
- 4
- Other Operating Expenses Total
- 25.3
- Total Operating Expense
- 150.4
- Operating Income
- 15.84
- Net Income Before Taxes
- 13.86
- Net Income
- 10.4
- Diluted Normalized EPS
- 2.15
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 151.56
- Selling/ General/ Admin Expenses Total
- 14.53
- Depreciation/ Amortization
- 3.85
- Other Operating Expenses Total
- 24.64
- Total Operating Expense
- 140.68
- Operating Income
- 10.88
- Net Income Before Taxes
- 9.64
- Net Income
- 7.38
- Diluted Normalized EPS
- 1.53
- Period
- 2024-09-30
- Total Assets
- 747.46
- Total Liabilities
- 250.15
- Total Equity
- 497.31
- Tangible Book Valueper Share Common Eq
- 98.27
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 11.61
- Cashfrom Investing Activities
- -23.79
- Cashfrom Financing Activities
- 5.97
- Net Changein Cash
- -6.21
- Period
- 2024-06-30
- Total Revenue
- 139.44
- Selling/ General/ Admin Expenses Total
- 13.35
- Depreciation/ Amortization
- 3.87
- Other Operating Expenses Total
- 22.03
- Total Operating Expense
- 125.15
- Operating Income
- 14.29
- Net Income Before Taxes
- 14.73
- Net Income
- 11.1
- Diluted Normalized EPS
- 4.6
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 186.08
- Selling/ General/ Admin Expenses Total
- 12.92
- Depreciation/ Amortization
- 3.59
- Other Operating Expenses Total
- 23.66
- Total Operating Expense
- 167.98
- Operating Income
- 18.1
- Net Income Before Taxes
- 25.18
- Net Income
- 18.62
- Diluted Normalized EPS
- 3.86
- Period
- 2024-03-31
- Total Assets
- 743.25
- Total Liabilities
- 252
- Total Equity
- 491.25
- Tangible Book Valueper Share Common Eq
- 97.41
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 43.26
- Cashfrom Investing Activities
- -43.55
- Cashfrom Financing Activities
- 0.99
- Net Changein Cash
- 0.69
- Period
- 2023-12-31
- Total Revenue
- 158.92
- Selling/ General/ Admin Expenses Total
- 13.74
- Depreciation/ Amortization
- 3.27
- Other Operating Expenses Total
- 21.97
- Total Operating Expense
- 138.6
- Operating Income
- 20.32
- Net Income Before Taxes
- 20.51
- Net Income
- 15.79
- Diluted Normalized EPS
- 3.27
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Kopran Technical
Moving Average
SMA
- 5 Day182.06
- 10 Day186.66
- 20 Day189.97
- 50 Day190.03
- 100 Day184.1
- 300 Day223.33
Kopran Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Fermenta Biotech
- 323.55
- 6.3
- 1.99
- 449
- 163
- 952.24
- Wanbury
- 285.2
- 9.8
- 3.56
- 330
- 151.1
- 935.97
- Kopran
- 185.55
- 0.55
- 0.3
- 369.2
- 157
- 898.85
- Bharat Parenterals
- 1140
- 40
- 3.64
- 1870
- 802
- 785.69
- Shree Ganesh Remedies
- 601.95
- -9.8
- -1.6
- 950.05
- 600
- 771.03
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Fermenta Biotech
- 12.28
- 2.6
- 3.78
- 2.92
- Wanbury
- 31.59
- 15.69
- -
- 5.62
- Kopran
- 23.21
- 1.73
- 12.24
- 8.66
- Bharat Parenterals
- -
- 2.38
- 6.54
- 1.93
- Shree Ganesh Remedies
- 33.49
- 5.32
- 21.94
- 20.52
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 15-May-25
- Audited Results & Final Dividend
- 11-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 16-May-24
- Audited Results & Final Dividend
- 07-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results & Dividend
- 10-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 11-Sept-24
- 16-May-24
- AGM
- 05-Sept-24
- 23-Jul-24
- AGM
- 14-Sept-23
- 17-Aug-23
- AGM
- 29-Aug-22
- 29-Jun-22
- AGM
- 31-Aug-21
- 12-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-May-25
- -
- -
- 3
- 16-May-24
- -
- 02-Sept-24
- 3
- 25-May-23
- -
- 07-Sept-23
- 3
- 27-May-22
- -
- 04-Aug-22
- 3
- 27-May-21
- -
- 05-Aug-21
- 1.5


